TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A study published in Nature Medicine links lower NRF2 levels in oligodendrocytes—cells that maintain myelin—to nerve-fiber abnormalities and faster cognitive decline. Human tissue findings show an association, while mouse experiments offer evidence of a possible causal role; whether NRF2-targeting drugs can help older adults remains unknown.
Researchers from the University of Edinburgh and the UK Dementia Research Institute report that oligodendrocytes, brain cells that maintain the insulating coating around nerve fibers, may contribute to cognitive decline when they become dysfunctional with age. The study, published in Nature Medicine, links lower levels of the protective protein NRF2 in these cells to abnormal myelin and nerve-fiber changes in human brain tissue, with experiments in mice providing evidence that reducing NRF2 can cause similar damage.
The human findings drew on the Lothian Birth Cohort 1936, whose members have had cognitive abilities tracked from childhood into older age. Of 1,091 people enrolled, 866 completed additional assessments after age 70. Researchers measured memory, processing speed and spatial reasoning between ages 70 and 82. Most participants experienced some decline, but the pace differed, allowing the team to compare changes in cognition with brain tissue collected after death from a subset of the cohort.
People who had declined more quickly tended to have fewer large nerve fibers and an abnormal buildup of myelin, the coating that helps electrical signals travel along nerve fibers. These tissue patterns were associated with the rate of cognitive change, rather than a person’s test performance at one particular age. The researchers also found lower levels of NRF2 in oligodendrocytes among people with more severe decline. The human observations establish associations; by themselves, they do not show that the cellular changes caused participants’ cognitive decline.
To test the possible mechanism, the team reduced NRF2 specifically in oligodendrocytes in mice. The animals developed excess myelin and lost large nerve fibers, changes resembling those found in human tissue. They also showed smaller improvements in cognitive performance as they aged. The experiments support a role for NRF2 in maintaining these cells, but the results in mice do not establish that a treatment targeting the pathway will prevent or reverse cognitive decline in people.
A New Target in Aging Brain Research
The findings challenge the idea that myelin-producing cells are uniformly protective throughout life. Oligodendrocytes normally support nerve fibers, but the study suggests their activity can become harmful when their protective systems falter. That shifts attention toward the health of the cells maintaining brain connections, not just the nerve fibers themselves.
The work also points to NRF2 as a possible therapeutic target. Drugs that affect this pathway are already used for other neurological conditions, including multiple sclerosis. Their existence could give researchers a starting point for future studies, but it is not evidence that those medicines are safe or effective for age-related cognitive decline. No treatment recommendation or clinical benefit for older adults was established by this research.
As an affiliate, we earn on qualifying purchases.
How the Cohort and Mouse Tests Fit
The cohort’s long record of cognitive testing gave researchers a way to examine the pace of change across later life, rather than relying on a single test taken at one age. That distinction matters: the reported tissue abnormalities tracked with how quickly cognition declined, according to the source report, not simply with performance at a snapshot in time.
The study combined that human evidence with experiments designed to test a potential mechanism. The human brain tissue provided a link between NRF2, myelin abnormalities and cognitive trajectories; the mouse work tested whether lowering NRF2 in oligodendrocytes could produce related changes. Together, the methods strengthen the biological case, while leaving open whether the same process can be modified to preserve cognition in humans.
““As the prevalence of cognitive decline is rising with an aging population and no current treatments exist, we are excited about this work as it points to a potential strategy for new therapeutic strategies to preserve cognitive ability in aging.””
— Veronique Miron, MRC Senior Non-Clinical Fellow and UK Dementia Research Institute group leader at the University of Edinburgh and St. Michael’s Hospital
As an affiliate, we earn on qualifying purchases.
What the Findings Do Not Establish
The study does not show that low NRF2 is the sole cause of cognitive decline, or that restoring it would prevent or reverse decline in people. The human tissue results are observational, and the experimental evidence comes from mice. The supplied report does not state the size of the human tissue subset or provide detailed effect estimates, making it difficult to assess the scale of the associations from the available information.
It is also not yet clear which existing drugs, if any, could safely affect this pathway in older adults, what dose or treatment window might be relevant, or whether changing NRF2 would improve real-world cognitive outcomes. The report notes previous research involving NRF2-targeting treatment and cognition in people with multiple sclerosis, but that does not establish a benefit for age-related decline.
cognitive health supplements for aging
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Testing NRF2 Treatments in People
The next steps are to determine how oligodendrocyte NRF2 changes over time, clarify how those changes relate to myelin and nerve-fiber damage, and test whether safely altering the pathway can protect cognition. Before any use for age-related decline, candidate drugs would need studies in people that assess both safety and cognitive outcomes.
The researchers’ findings identify a potential research direction, not a confirmed therapy. Until human trials establish whether the pathway can be targeted effectively, the clinical implications remain uncertain.
As an affiliate, we earn on qualifying purchases.
Key Questions
Which brain cells are implicated in the study?
The study focuses on oligodendrocytes, cells that produce and maintain myelin, the insulating coating around nerve fibers.
What is NRF2?
NRF2 is a protein involved in regulating genes that help cells defend against damage and maintain normal function. The researchers found lower levels of it in oligodendrocytes in people with more severe cognitive decline.
Does the study prove these cells cause cognitive decline in people?
No. Human brain tissue findings show associations. Experiments in mice provide evidence that reducing NRF2 in oligodendrocytes can cause related abnormalities in those animals, but they do not prove the same causal effect in people.
The study points to drugs that act on the NRF2 pathway as a possible research avenue. It does not establish that any multiple sclerosis medicine benefits older adults with age-related cognitive decline.
Source: rss
Evergreen bestsellers Picks
bestsellers
As an affiliate, we earn on qualifying purchases.
